The Medicines Evaluation Board (MEB) has come to the point that their scientific agenda for the coming years is ready to be launched. Our eye is focused on Europe and, even further, on International collaboration at the level of regulatory science. The roadmap towards this collaboration starts with taking responsibility in the governance of a regulatory science network in The Netherlands (RSnN), and strengthen knowledge and competence between regulators, academia and industry.

Strengthening knowledge and competence
Regulatory science is the R&D of the agency

Facts & figures

To put some figures in place, from 2011-2016, the regulatory science program brought about 231 scientific publications in peer reviewed scientific journals and delivered 18 PhD theses in close collaboration with the universities of Utrecht, Groningen, and Rotterdam. Another 4 PhD theses’ were supported through the TI Pharma Escher program, now Lygature Escher. In addition, the MEB supported the RIVM Health Chain Research program, that is nearing completion, and another 5 scientific projects in collaboration with external parties. The MEB hosted 69 bachelor- and master students from various universities, academic and technical, for short- and longer term internships.

The shorthand summarizes the MEB’s regulatory science achievements, and presents topics for the near future.

Scientific publications in peer reviewed journals
A| Scientific publications in peer reviewed journals
201637
201555
201442
201335
201242
Source table as .csv (100 bytes)
Number of Phd's completed
PhD/MEBPhD/Escher
20166
20153
20142
20134
201214
Source table as .csv (67 bytes)
Number of (under)graduate students
A|Number of (Under) Graduate students
201617
20159
20149
201314
201211
Source table as .csv (83 bytes)
Distribution of universities
B. Distribution universities
Utrecht University43%
Technical University Utrecht /The Hague23%
Leiden University12%
University College Roosevelt8%
Other12%
Source table as .csv (167 bytes)